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Immune-based interventions are steadily broadening therange of choices among cancer prevention and treatment
modalities. Recent major advances in the therapy of lym-
phoid malignancies and prevention of cervical cancer (to
name a few) fuel the interest of investigators and clinicians
who tried for decades to exploit the potential of the immune
system to control the disease. Lung cancer presents a more
challenging group of diseases, where major breakthroughs in
immunotherapy or vaccination are yet to be seen. The fol-
lowing update may elicit cautious optimism for some areas of
this endeavor.
Dr. Scott Antonia summarized the essential processes
by which the immune system recognizes and responses to
tumor-associated antigens (TAAs) on tumor cells. From the
MHC Class I antigen processing pathway, dendritic cell-
based activation to cytotoxic T lymphocytes (CTLs) to the list
of various types of tumor-associated antigens and evidence of
the presence of specific CTLs for individual TAAs; experi-
mental and clinical data provide the rationale for the devel-
opment of tumor vaccines (Table 1).
Nevertheless, once vaccines are tested in clinics, there
is a “glass ceiling” with a tumor response rate of 5 to 10%.
Efficacy can only be improved by developing combination
immunotherapy with the use of (1) immunomodulatory
agents (T-cell growth factors, anticheckpoint, or costimula-
tory agents); (2) elimination of suppressive cells; (3) inacti-
vation of suppressive cytokines and factors in the tumor
microenvironment; and (4) sequencing with chemotherapy.
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p53 Vaccine
A good example of a dendritic cell vaccine was the use
of p53 as antigenic target in small cell lung cancer (SCLC).
Patient-derived dendritic cells were infected with an adeno-
viral vector containing the p53 gene (Ad.p53-DC) and ad-
ministered back to patients. Of 31 subjects, 16 (52%) showed
specific responses with three (10%) reaching a complete
response. The treatment caused no significant toxicities. A
randomized phase II trial testing salvage chemotherapy in
extensive stage SCLC patients after the Ad.p53-DC vaccine
is planned.1
MAGE-A3 Vaccine
Melanoma-associated antigen 3 is a tumor-specific an-
tigen that in humans is encoded by the MAGEA3 gene. It is
present in 30 to 50% of NSCLC. The MAGE-A3 vaccine is
made of the ProtD-A3/His recombination fusion protein with
a sequence of histidine residues produced in Escherichia coli
and combined with the adjuvant ASO2B. Dr. Ramaswamy
Govindan presented results of a randomized phase II trial in
stage IB or II NSCLC with active vaccination versus placebo
that yielded enough enthusiasm to design the four-arm
MAGRIT phase III study in resected MAGE-A3-positive
NSCLC.2 Patients can receive platinum-based chemotherapy
or not (clinical decision) and both groups are randomized to
MAGE-A3 or placebo. Disease-free survival is the primary
objective. As of January 2011, 9726 patients were screened
and 1547 randomized in 34 participating countries over the
world.
MUC1 (Stimuvax)
Another TAA presented by Dr. Govindan, is Mucin 1
(MUC1), a mucinous glycoprotein overexpressed in several
human malignancies. A peptide vaccine L-BLP25 (Stimuvax)
against the exposed core peptide of MUC1 induced cellular
immune response in preclinical studies. In a phase IIB study,
Stimuvax with best supportive care showed superior overall
survival in stage IIIB patients against best supportive care
only (3-year survival 49 versus 27%). The phase III study
randomized against placebo and best supportive care was
halted because of a single case of encephalitis but was
reopened in June 2010.3
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TABLE 1. Tumor Vaccine Approaches
TAA-derived peptides in adjuvants
Vaccinia and pox viral vectors for prime boost
“Loaded” autologous dendritic cells
Tumor cell/dendritic cell hybrids
Gene-modified tumor cells
Tumor cells admixed with “bystander cells” engineered to secrete cytokines
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MUC1 (TG4010-MVA MUC1-IL2)
Dr. Jean-Marc Limacher introduced TG4010, a targeted
immunotherapy agent containing a modified Vaccinia virus
strain Ankara coding for MUC1 and interleukin 2. So far, two
phase I and five Phase II trials yielded a good safety profile
with proof of activity in prostate cancer and cellular immu-
nogenicity against MUC1. A phase IIB study randomized 148
advanced, MUC1-positive NSCLC patients to a cisplatin/
gemcitabine regimen with or without a weekly subcutaneous
injection of TG4101 for 6 weeks and then once every 3 weeks
until progressive disease. There was a trend of a better
response in TG4010-treated patients. A significantly in-
creased overall survival was seen in TG4010-treated patients
with normal levels of activated natural killer (NK) cells at
baseline. The opposite result came out in patients with high
level activated NK cells that may kill cytotoxic T cells. Phase
IIB/3 study will be launched in the second half of 2011.4
Talactoferrin Alfa
Talactoferrin alfa (TLF) is a unique recombinant hu-
man lactoferrin with immunomodulatory properties. Oral
TLF mediates its anticancer activity by the activation of
tumor antigen-bearing dendritic cells in gut-associated lym-
phoid tissue. Dr. Giuseppe Giaccone reported the promising
results of the phase II study of TLF versus best supportive
care (LF-0201), where overall survival benefit of a well-
tolerated treatment was seen in non-SCLC (NSCLC) pa-
tients.5 Two phase III studies are currently in progress:
Fortis-M is a randomized, double-blinded, placebo-controlled
study of oral talactoferrin in addition to best supportive care
in patients with NSCLC who have failed two or more prievi-
ous regimens and Fortis-C, a randomized, double-blinded,
placebo-controlled study of oral talactoferrin in combination
with carboplatin and paclitaxel as first-line therapy in patients
with locally advanced or metastatic NSCLC.
Anti-CTLA-4 (Ipilimumab)
Targeting of the immunosuppressive immunoglobulin
CTLA4 expressed on T cells has shown anticancer activity in
melanoma, brain metastases, prostate, renal, pancreatic, lung
cancers, and lymphoma. In March 2011, the US Food and
Drug Administration (FDA) approved ipilimumab (Yervoy),
the antibody against CTLA4, for treatment of patients with
late-stage melanoma. Dr. Joel Neal presented a lung cancer
phase II trial (BMS CA 184-041) where phased ipilimumab
in combination with paclitaxel/carboplatin extended progres-
sion-free survival of advanced stage NSCLC and extensive
stage SCLC patients. A statistically nonsignificant numerical
improvement in overall survival was observed in the phased
schedule. The safety profile was comparable with other
ipilimumab studies. A fatal (grade 5) toxic epidermal
necrolysis (TEN) was observed in one patient in the arm
where ipilimumab was concurrently administered with
chemotherapy. A phase III study in 800 patients with
squamous NSCLC is planned that will compare carbopla-
tin/paclitaxel  ipilimumab.6
Anti-PD-1 (BMS-936558/MDX1106/ONO-4538)
The cell surface protein Programmed Death 1 (PD-1) is
a member of the extended CD28/CTLA-4 family of T cell
regulators. Similar to CTLA4, it also regulates negatively the
activity of memory and regulatory T cells to tumors. Dr. Julie
Brahmer reported that the ligand of PD-1, PD-L1/B7H1 is
more expressed in adeno- than in squamous cell lung cancer
and indicates worse prognosis. An IgG4 PD-1-blocking an-
tibody (BMS-936558) with no antibody or complement de-
pendent cellular cytotoxicity activity is currently in clinical
testing. A phase I single-agent/dose study showed responses
in melanoma, renal and colorectal cancers, and a mixed
response in NSCLC. The agent was well tolerated and the
receptor occupancy lasted for 3 months.7 A multidose/single-
agent phase I study (once every 2 weeks, doses 1, 3, or 10
mg/kg) generated durable responses with manageable adverse
events (only 5.7% subjects experienced grade 3 or 4 events).
One partial response, five cases of stable disease, and five of
progressive disease in NSCLC were observed. Therapy with
BMS-936558 to enhance endogenous antitumor immunity,
either alone or in combination with other therapeutic modal-
ities, warrants further study.
PD-1-Ligand (AMP-224)
The natural ligand for PD-1, B7-DC is expressed on
dendritic cells and macrophages. AMP-224 is a B7-DC Fc
fusion molecule that restores immune function and has anti-
tumor activities. Dr. Sol Langermann shared the results from
preclinical studies with AMP-224 in a CT26 tumor model.
Besides eradication of the tumor, the agent promoted the
establishment of long-term antitumor activity through multi-
ple mechanisms of action. First-in-human study is to be
initiated in 2011.
Picornavirus SVV-001
This serendipitously discovered virus has a selective
tropism for tumors with neuroendocrine features. Dr. Charles
Rudin summarized the preclinical work that demonstrated
efficacy in xenograft, syngeneic, orthotopic, and metastatic
models of SCLC. Intravenous SVV-001 administration in a
phase I trial was well tolerated at doses up to 1011 vp/kg, with
predictable viral clearance kinetics, intratumoral viral repli-
cation, and evidence of antitumor activity in patients with
small cell lung cancer.8 Phase II clinical evaluation in small
cell lung cancer has been initiated.
Future Directions
The success of immunotherapy in lung cancer will
depend on the careful selection of patients responsive to this
modality. Further refinement of the interventions together
with favorable combinations regimens may lead to positive
long-term results, a hallmark often seen in preclinical immu-
notherapy models.
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